FDA Panel Says Data Don't Show Naproxen Is Safer NSAID

Law360, New York (February 11, 2014, 7:27 PM EST) -- A U.S. Food and Drug Administration panel voted Tuesday that there is not enough scientific proof to support claims that naproxen, a painkiller sold as Aleve by drug giant Bayer Corp., is safer than other nonsteroidal anti-inflammatory drugs including ibuprofen.

The panel voted 16-9 that there is not enough data to show that naproxen poses lower heart health risks compared with other NSAIDs including ibuprofen, which rival drugmaker Pfizer Inc. markets as Advil, and aspirin. The vote came on the second day of a joint meeting...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.